Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão
DOI:
https://doi.org/10.11606/s1518-8787.2020054003278Palavras-chave:
Seroepidemiologic Studies, Coronavirus Infections, Immunity, Herd, MortalityResumo
OBJECTIVE: To estimate the seroprevalence of SARS-CoV-2 in the state of Maranhão, Brazil. METHODS: A population-based household survey was performed, from July 27, 2020 to August 8, 2020. The estimates considered clustering, stratification and non-response. Qualitative detection of IgM and IgG antibodies was performed in a fully-automated Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay on the Cobas® e601 analyzer (Roche Diagnostics). RESULTS: In total, 3,156 individuals were interviewed. Seroprevalence of total antibodies against SARS-CoV-2 was 40.4% (95%CI 35.6-45.3). Population adherence to non-pharmaceutical interventions was higher at the beginning of the pandemic than in the last month. SARS-CoV-2 infection rates were significantly lower among mask wearers and among those who maintained social and physical distancing in the last month compared to their counterparts. Among the infected, 26.0% were asymptomatic. The infection fatality rate (IFR) was 0.14%, higher for men and older adults. The IFR based on excess deaths was 0.28%. The ratio of estimated infections to reported cases was 22.2. CONCLUSIONS: To the best of our knowledge, the seroprevalence of SARS-CoV-2 estimated in this population-based survey is one of the highest reported. The local herd immunity threshold may have been reached or might be reached soon.
Referências
Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Baltimore, MD: CCSE; 2020 [cited 2020 Sept 21]. Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
The Lancet. COVID-19 in Brazil: “So what?” Lancet. 2020;395(10235):1461. https://doi.org/10.1016/S0140- 6736(20)31095-3
Candido DS, Claro IM, Jesus JG, Souza WM, Moreira FRR, Dellicour S, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science. 2020;369(6508):1255-60. https://doi.org/10.1126/science.abd2161
Instituto Brasileiro de Geografia e Estatística. Projeção da população por sexo e idades simples, em 1º de julho - 2010/2060. Rio de Janeiro: IBGE; 2018 [cited 2020 Aug 18]. Available from: ftp://ftp.ibge.gov.br/Projecao_da_Populacao/Projecao_da_Populacao_2018/projecoes_2018_populacao_idade_simples_2010_2060.xls
Secretaria de Estado da Saúde do Maranhão. Bol Epidemiol COVID-19. 20 ago 2020 [cited 2020 Aug 21]. Available from:
https://www.saude.ma.gov.br/wp-content/uploads/2020/08/BOLETIM-20-08.pdf
Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity. 2020;52(5):737-41. https://doi.org/10.1016/j.immuni.2020.04.012
Aguas R, Corder RM, King JG, Gonçalves G, Ferreira MU, Gomes MGM. Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics. medRxiv [Preprint]. 2020 [posted 2020 Jul 24]. https://doi.org/10.1101/2020.07.23.20160762
Britton T, Ball F, Trapman P. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. Science. 2020;369(6505):846-9. https://doi.org/10.1126/science.abc6810
Hallal PC, Hartwig FP, Horta BL, Victora GD, Silveira M, Struchiner C, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. Lancet Glob Heal. 2020;8(11):e1390–8.
https://doi.org/10.1016/S2214-109X(20)30387-9
Ioannidis J. The infection fatality rate of COVID-19 inferred from seroprevalence data. medRxiv [Preprint]. 2020 [posted 2020 Jul 14]. https://doi.org/10.1101/2020.05.13.20101253
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo M, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-44.
https://doi.org/10.1016/S0140-6736(20)31483-5
Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. 2020;48:23-29. e4. https://doi.org/10.1016/j.annepidem.2020.06.004
Tess BHC, Alves MCGP, Reinach F, Granato CFH, Rizzati EG, Pintão MC, et al. Inquérito domiciliar para monitorar a soroprevalência da infecção pelo vírus SARS-CoV-2 em adultos no município de São Paulo. São Paulo, SP: Projeto SoroEPI-MSP; 2020 [cited 2020 Aug 21]. Available from: https://0dea032c-2432-4690-b1e5-636d3cbeb2bf.filesusr.com/ugd/6b3408_90141a5c289e43cfb75c2ce6408d299e.pdf
Buss LF, Prete Jr CA, Abrahim CMM, Mendrone Jr AM, Salomon T, Almeida-Neto C, et al. COVID-19 herd immunity in the Brazilian Amazon. medRxiv [Preprint]. 2020 [posted 2020 Sept 21]. https://doi.org/10.1101/2020.09.16.20194787
Russell TW, Hellewell J, Jarvis CI, Zandvoort K, Abbott S, Ratnayake R, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Eurosurveillance. 2020;25(12):2000256. https://doi.org/10.2807/1560-7917.ES.2020.25.12.2000256
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669-77. https://doi.org/10.1016/S1473-3099(20)30243-7
Ing AJ, Cocks C, Green JP. COVID-19: in the footsteps of Ernest Shackleton. Thorax. 2020;75(8):693-4. https://doi.org/10.1136/thoraxjnl-2020-215091
Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. Int J Infect Dis. 2020;101:138–48. https://doi.org/10.1016/j.ijid.2020.09.1464
Menezes AMB, Victora CG, Hartwig FP, Silveira MF, Horta BL, Barros AJD, et al. High prevalence of symptoms among Brazilian subjects with antibodies against 2 SARS-CoV-2: a nationwide household survey. medRxiv [Preprint]. 2020 [posted 2020 Aug 12]. https://doi.org/10.1101/2020.08.10.20171942
Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. medRxiv [Preprint]. 2020 [posted 2020 Sept 13] https://doi.org/10.1101/2020.05.10.20097543
Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368(6490):489-93. https://doi.org/10.1126/science.abb3221
UNESCO. The International Standard Classification of Education ISCED 2011. Vol 5. Québec (CA): UNESCO Institute for Statistics; 2012 [cited 2020 Aug 21]. Available from: https://web.archive.org/web/20170106011231/https://uis.unesco.org/sites/default/files/documents/international-standard-classification-of-education-isced-2011-en.pdf
Travassos C, Williams DR. The concept and measurement of race and their relationshipto public health: a review focused on Brazil and the United States. Cad Saude Publica. 2004;20(3):660-78. https://doi.org/10.1590/S0102-311X2004000300003
Muench P, Jochum S, Wenderoth V, Ofenloch-Haehnle B, Hombach M, Strobl M, et al. Development and validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol. 2020;58(10):e01694-20. https://doi.org/10.1128/JCM.01694-20
McGough SF, Johansson MA, Lipsitch M, Menzies NA. Nowcasting by Bayesian Smoothing: a flexible, generalizable model for real-time epidemic tracking. PLoS Comput Biol. 2020;16(4):e1007735. https://doi.org/10.1371/journal.pcbi.1007735
Conselho Nacional de Secretários de Saúde. Painel de análise do excesso de mortalidade por causas naturais no Brasil em 2020. Brasília, DF: CONASS; 2020 [cited 2020 Sept 21]. Available from: https://www.conass.org.br/indicadores-de-obitos-por-causas-naturais/
Marinho F, Torrens A, Teixeira R, França E, Nogales AM, Xavier D, et al. Excess mortality in Brazil: detailed description of trends in mortality during the COVID-19 pandemic. New York: Vital Strategies; 2020 [cited 2020 Aug 21]. Available from:
https://www.vitalstrategies.org/wp-content/uploads/RMS_ExcessMortality_BR_Report-English.pdf
Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, Pérez-Olmeda M, Yotti R, Oteo J, et al. SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study. medRxiv [Preprint]. 2020 [posted 2020 Aug 7]. https://doi.org/10.1101/2020.08.06.20169722
Health Information and Quality Authority. Evidence summary of the immune response following infection with SARS- CoV-2 or other human coronaviruses. Dublin (IRL): HIQA; 2020 [cited 2020 Aug 21]. Available from: https://www.hiqa.ie/sites/default/files/2020-06/Evidencesummary_SARS-CoV-2-immune-response.pdf
Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158-68.e14. https://doi.org/10.1016/j.cell.2020.08.017
Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-1501.e15. https://doi.org/10.1016/j.cell.2020.05.015
Long QX, Tang XJ, Shi QL, Deng HJ, Yuan J, HU JL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4. https://doi.org/10.1038/s41591-020-0965-6
Perkmann T, Perkmann-Nagele N, Breyer MK, Breyer-Kohansal-R, Bugghuber OC, Hartl S, et al. Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity. Clin Chem. 2020 Aug 10;hvaa198. https://doi.org/10.1093/clinchem/hvaa198. Epub ahead of print
Bastos ML, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;370:m2516. https://doi.org/10.1136/bmj.m2516
Flower B, Brown JC, Simmons B, Moshe M, Frise R, Penn R, et al. Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. Thorax. 2020 Aug 12;thoraxjnl-2020-215732.
https://doi.org/10.1136/thoraxjnl-2020-215732. Epub ahead of print.
Ward H, Atchison CJ, Whitaker M, Ainslie KEC, Elliott JE, Okell LC, et al. Antibody prevalence for SARS-CoV-2 in England following the first peak of the pandemic: REACT2 study in 100,000 adults. medRxiv [Preprint]. 2020 [posted 2020 Aug 21]. https://doi.org/10.1101/2020.08.12.20173690
Mahase E. Covid-19: two antibody tests are “highly specific” but vary in sensitivity, evaluations find. BMJ. 2020;369;m2066. https://doi.org/10.1136/bmj.m2066
Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. medRxiv [Preprint]. 2020 [posted 2020 Aug 6]. https://doi.org/10.1101/2020.08.05.20169128
Tess BH, Granato CFH, Alves MCGP, Pintão MC, Rizzatti E, Nunes MC, et al. SARS-CoV-2 seroprevalence in the municipality of São Paulo, Brazil, ten weeks after the first reported case. medRxiv [Preprint]. 2020 [posted 2020 June 29,].
https://doi.org/10.1101/2020.06.29.20142331
Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-87. https://doi.org/10.1016/S0140-6736(20)31142-9
Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257-61. https://doi.org/10.1038/s41586-020-2405-7
Walker PGT, Whittaker C, Watson OJ, Baguelin M, Winskill P, Hamlet A, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020;369(6502):413-22. https://doi.org/10.1126/science.abc0035
Kenyon C. COVID-19 infection fatality rate associated with incidence: a population-level analysis of 19 Spanish autonomous communities. Biology (Basel). 2020;9(6):128. https://doi.org/10.3390/biology9060128
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2020 Revista de Saúde Pública
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
